David Ghasemi
@davidrghasemi.bsky.social
Paediatric oncology resident @UKE Hamburg, Clinician Scientist @UKE Hamburg / KiTZ Heidelberg. Interested in paediatric #oncology, #neurooncology, and #genetics. Opinions are mine only.
Our study presenting the results of the E-HIT2000 trial and a new clinical-molecular stratification model for paediatric #ependymoma is finally online in Neuro-Oncology! 🎉 1/3
share.google/6h9yoFqhaFtQ...
share.google/6h9yoFqhaFtQ...
Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registries
AbstractBackground. Current treatment strategies for pediatric intracranial ependymoma do not consider molecular heterogeneity. Here, we evaluated molecula
share.google
October 8, 2025 at 5:35 PM
Our study presenting the results of the E-HIT2000 trial and a new clinical-molecular stratification model for paediatric #ependymoma is finally online in Neuro-Oncology! 🎉 1/3
share.google/6h9yoFqhaFtQ...
share.google/6h9yoFqhaFtQ...
The ITCC Scientific Days in Newcastle have been a great meeting - thank you to the organisers! It was a pleasure to contribute to the excellent programme by presening our latest approach to #ependymoma stratification! #cancer #neurooncology
March 30, 2025 at 3:05 PM
The ITCC Scientific Days in Newcastle have been a great meeting - thank you to the organisers! It was a pleasure to contribute to the excellent programme by presening our latest approach to #ependymoma stratification! #cancer #neurooncology
Reposted by David Ghasemi
Blinatumomab has been shown to improve outcomes in children with relapsed B-cell ALL, but the effects in children with newly diagnosed disease have been unclear. Research findings are summarized in a new Quick Take video. youtu.be/oADeOZpNYY8
#MedSky #Hematology
#MedSky #Hematology
Blinatumomab in B-Cell Acute Lymphoblastic Leukemia | NEJM
YouTube video by NEJM Group
youtu.be
February 28, 2025 at 8:11 PM
Blinatumomab has been shown to improve outcomes in children with relapsed B-cell ALL, but the effects in children with newly diagnosed disease have been unclear. Research findings are summarized in a new Quick Take video. youtu.be/oADeOZpNYY8
#MedSky #Hematology
#MedSky #Hematology
Reposted by David Ghasemi
Our free webinars are back!
Today we had the pleasure of listening to Dr Ulrich Schüller from the Research Institute Children’s Cancer Center Hamburg, talking about his work on the molecular diversity of spinal ependymomas.
Today we had the pleasure of listening to Dr Ulrich Schüller from the Research Institute Children’s Cancer Center Hamburg, talking about his work on the molecular diversity of spinal ependymomas.
February 24, 2025 at 12:56 PM
Our free webinars are back!
Today we had the pleasure of listening to Dr Ulrich Schüller from the Research Institute Children’s Cancer Center Hamburg, talking about his work on the molecular diversity of spinal ependymomas.
Today we had the pleasure of listening to Dr Ulrich Schüller from the Research Institute Children’s Cancer Center Hamburg, talking about his work on the molecular diversity of spinal ependymomas.
Achievements such as this would have been thought of as impossible only a couple of decades ago. #Science delivers. But in a world where scientists are attacked, drowned in bureaucracy and regulations, and cut off their funding, miracles like the cure of #SMA will become rare.
A two-and-a-half-year-old girl shows no signs of a rare genetic disorder, after becoming the first person to be treated for the motor-neuron condition while in the womb.
https://go.nature.com/41a7Zzj
https://go.nature.com/41a7Zzj
Rare genetic disorder treated in womb for the first time
The child, who is now almost three years old, shows no signs of the often fatal motor neuron disease.
go.nature.com
February 20, 2025 at 8:59 PM
Reposted by David Ghasemi
# REVIEW 🚨
Simovic-Lorenz & Ernst from @dkfz.bsky.social discuss mechanisms of #chromothripsis, its impact on cancer and vulnerabilities of chromothriptic tumours.
📖 ⬇️
Simovic-Lorenz & Ernst from @dkfz.bsky.social discuss mechanisms of #chromothripsis, its impact on cancer and vulnerabilities of chromothriptic tumours.
📖 ⬇️
Chromothripsis in cancer - Nature Reviews Cancer
go.nature.com
February 14, 2025 at 6:17 PM
# REVIEW 🚨
Simovic-Lorenz & Ernst from @dkfz.bsky.social discuss mechanisms of #chromothripsis, its impact on cancer and vulnerabilities of chromothriptic tumours.
📖 ⬇️
Simovic-Lorenz & Ernst from @dkfz.bsky.social discuss mechanisms of #chromothripsis, its impact on cancer and vulnerabilities of chromothriptic tumours.
📖 ⬇️
Reposted by David Ghasemi
#REVIEW 🚨
Genetic predisposition is the major known cause of cancer in children. In our Feb issue, Kratz highlights the genetic architecture of it, focusing on its roles in cancer prediction, prevention, surveillance and therapy.
📖 👇
https://bit.ly/3ZHhZ...
Genetic predisposition is the major known cause of cancer in children. In our Feb issue, Kratz highlights the genetic architecture of it, focusing on its roles in cancer prediction, prevention, surveillance and therapy.
📖 👇
https://bit.ly/3ZHhZ...
Re-envisioning genetic predisposition to childhood and adolescent cancers - Nature Reviews Cancer
Genetic predisposition is the major known cause of cancer in children and adolescents. In this Review, Kratz highlights the genetic architecture of cancer in children and adolescents, examining cancer predisposition syndromes, cancer predisposition genes, embryonic mosaicism and polygenic risk...
bit.ly
February 17, 2025 at 3:32 PM
#REVIEW 🚨
Genetic predisposition is the major known cause of cancer in children. In our Feb issue, Kratz highlights the genetic architecture of it, focusing on its roles in cancer prediction, prevention, surveillance and therapy.
📖 👇
https://bit.ly/3ZHhZ...
Genetic predisposition is the major known cause of cancer in children. In our Feb issue, Kratz highlights the genetic architecture of it, focusing on its roles in cancer prediction, prevention, surveillance and therapy.
📖 👇
https://bit.ly/3ZHhZ...
Reposted by David Ghasemi
Ever wondered how different biological datasets can be combined in the best way (e.g. data from #transcriptomics #proteomics #DNAmethylomics)?
Have a look at our #review paper describing challenges of #data integration and available #algorithms and tools.
doi.org/10.1002/pmic...
Have a look at our #review paper describing challenges of #data integration and available #algorithms and tools.
doi.org/10.1002/pmic...
Computational Methods for Data Integration and Imputation of Missing Values in Omics Datasets
Molecular profiling of different omic-modalities (e.g., DNA methylomics, transcriptomics, proteomics) in biological systems represents the basis for research and clinical decision-making. Measurement...
doi.org
February 11, 2025 at 9:01 PM
Ever wondered how different biological datasets can be combined in the best way (e.g. data from #transcriptomics #proteomics #DNAmethylomics)?
Have a look at our #review paper describing challenges of #data integration and available #algorithms and tools.
doi.org/10.1002/pmic...
Have a look at our #review paper describing challenges of #data integration and available #algorithms and tools.
doi.org/10.1002/pmic...
Amazing initiative! 👏🏾👏🏾👏🏾 #childhoodcancer #globalhealth
In many countries, childhood cancer medicines are out of reach. St. Jude Children’s Research Hospital is collaborating with the @who.int, @unicef.org and PAHO to change that.
Global Platform for Access to Childhood Cancer Medicines
YouTube video by St. Jude Children's Research Hospital
www.youtube.com
February 11, 2025 at 5:23 PM
Amazing initiative! 👏🏾👏🏾👏🏾 #childhoodcancer #globalhealth
Reposted by David Ghasemi
Gene editing technology began by people studying salt marshes. Ozempic began by folks studying the venom of Gila Monsters. Support for basic science has empowered us to understand our world. Tethering it to applications health has transformed and saved countless lives.
February 8, 2025 at 1:45 PM
Gene editing technology began by people studying salt marshes. Ozempic began by folks studying the venom of Gila Monsters. Support for basic science has empowered us to understand our world. Tethering it to applications health has transformed and saved countless lives.
Great to see this paper on naturally T cell antigens in #medulloblastoma online! Congratulations to all authors - I'm happy that I was able to contribute a little bit!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics - Nature Communications
Medulloblastoma in children is a difficult cancer to treat and the immune response to this tumour is not fully understood. Here the authors characterise and validate T cell epitopes from these cancers...
www.nature.com
February 6, 2025 at 9:30 AM
Great to see this paper on naturally T cell antigens in #medulloblastoma online! Congratulations to all authors - I'm happy that I was able to contribute a little bit!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by David Ghasemi
We are more than happy that our publication "The Immunopeptidomic Landscape of Ependymomas Provides Actionable Antigens for T Cell-Based Immunotherapy" is accepted by Neurooncology Advances.
academic.oup.com/noa/advance-...
Check it out ;)
@unituebingen.bsky.social
@hih-tuebingen.bsky.social
academic.oup.com/noa/advance-...
Check it out ;)
@unituebingen.bsky.social
@hih-tuebingen.bsky.social
The Immunopeptidomic Landscape of Ependymomas Provides Actionable Antigens for T Cell-Based Immunotherapy
AbstractBackground. Ependymoma are primary tumors of the nervous system. Due to their growth pattern, many ependymomas can be managed with neurosurgical re
academic.oup.com
January 16, 2025 at 2:42 PM
We are more than happy that our publication "The Immunopeptidomic Landscape of Ependymomas Provides Actionable Antigens for T Cell-Based Immunotherapy" is accepted by Neurooncology Advances.
academic.oup.com/noa/advance-...
Check it out ;)
@unituebingen.bsky.social
@hih-tuebingen.bsky.social
academic.oup.com/noa/advance-...
Check it out ;)
@unituebingen.bsky.social
@hih-tuebingen.bsky.social
Reposted by David Ghasemi
A great way to start into the new year! Happy to see our paper on Biglycan as a potential risk stratificator in ZFTA-#ependyoma online. Special congratulations to my colleagues Konstantin, Kristian, and Andrey, who jointly led this study! 🥳
actaneurocomms.biomedcentral.com/articles/10....
actaneurocomms.biomedcentral.com/articles/10....
Biglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling - Acta Neuropathologica Communications
Recent genomic studies have allowed the subdivision of intracranial ependymomas into molecularly distinct groups with highly specific clinical features and outcomes. The majority of supratentorial epe...
actaneurocomms.biomedcentral.com
January 10, 2025 at 10:37 PM
A great way to start into the new year! Happy to see our paper on Biglycan as a potential risk stratificator in ZFTA-#ependyoma online. Special congratulations to my colleagues Konstantin, Kristian, and Andrey, who jointly led this study! 🥳
actaneurocomms.biomedcentral.com/articles/10....
actaneurocomms.biomedcentral.com/articles/10....
Hey there! As always somewhat late to the latest social network party, but let's see whether bluesky has indeed become science twitter from a couple of years ago. Looking forward to meeting many new and familiar friends and colleagues here!
January 10, 2025 at 10:35 PM
Hey there! As always somewhat late to the latest social network party, but let's see whether bluesky has indeed become science twitter from a couple of years ago. Looking forward to meeting many new and familiar friends and colleagues here!